BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 11, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the development of therapeutics to improve cardiovascular health, today announced the addition of an exclusive consortium of companies led by Slanmhor Pharmaceutical, Inc. (Slanmhor) to its planned active pharmaceutical ingredient (API) global supply chain for Vascepa® (icosapent ethyl) capsules. Slanmhor was spun-out from Ocean Nutrition Canada (ONC) prior to the May 2012 acquisition of ONC by Royal DSM N.V. (DSM), a global leader in life sciences and materials sciences. Amarin now has a total of four API suppliers for Vascepa API for Amarin to utilize to support the global commercialization of Vascepa, subject to appropriate regulatory approvals.
Amarin Announces Additional Vascepa(R) (icosapent Ethyl) Supplier
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.